CMMB
Chemomab Therapeutics Ltd.
OpenVolumeMkt capP/EEPSDiv yield
Day – 52-wk –
Expected move
InputsNext report
Last report
Largest filed tie
13F top-10 QoQ
Top fund weight
Chemomab Therapeutics Ltd.
Expected move
InputsNext report
Last report
Largest filed tie
13F top-10 QoQ
Top fund weight
Largest filed tie
0
filed ties
—
No changes.
No changes.
Chemomab Therapeutics Ltd., a clinical-stage biotech company, discovers and develops therapeutics for the treatment of inflammation and fibrosis. The company's lead clinical product candidate is CM-101, a humanized monoclonal antibody that hinders the basic function of soluble chemokine CCL24 for the treatment of primary sclerosing cholangitis (PSC) and systemic sclerosis (SSc). The company was formerly known as Anchiano Therapeutics Ltd. and changed its name to Chemomab Therapeutics Ltd. in March 2021. Chemomab Therapeutics Ltd. was incorporated in 2011 and is based in Tel Aviv, Israel.
Chemomab Therapeutics Ltd., a clinical-stage biotech company, discovers and develops therapeutics for the treatment of inflammation and fibrosis. The company's lead clinical product candidate is CM-101, a humanized monoclonal antibody that hinders the basic function of soluble chemokine CCL24 for the treatment of primary sclerosing cholangitis (PSC) and systemic sclerosis (SSc). The company was formerly known as Anchiano Therapeutics Ltd. and changed its name to Chemomab Therapeutics Ltd. in March 2021. Chemomab Therapeutics Ltd. was incorporated in 2011 and is based in Tel Aviv, Israel.
No peers for Chemomab Therapeutics Ltd. yet.
No peers for Chemomab Therapeutics Ltd. yet.
No thesis.
Annual filing, covered
20-F parsed · Mar 23 '26
Supply-chain ties, covered
None disclosed
Fund holders, covered
No N-PORT holders
13F holdings, covered
13F quarter · Jun 30 '26
Management, not covered
Not covered · DEF 14A, 8-K 5.02
Company IR feed, not covered
News via newswires & EDGAR
Products, patents, hiring, not covered
Not covered
Annual filing, covered
20-F parsed · Mar 23 '26
Supply-chain ties, covered
None disclosed
Fund holders, covered
No N-PORT holders
13F holdings, covered
13F quarter · Jun 30 '26
Management, not covered
Not covered · DEF 14A, 8-K 5.02
Company IR feed, not covered
News via newswires & EDGAR
Products, patents, hiring, not covered
Not covered
Chemomab Therapeutics Ltd.
1.13
—
Tall tick = annual report · Source: EDGAR
Expected move
No implied move.
| Manager | Value | % base | |
|---|---|---|---|
| Citadel | $154,404 | 25.09% | +48.50% |
| ADAR1 | $129,600 | 21.06% | 0.00% |
| Kestra Private Wealth Services | $99,970 | 16.25% | 0.00% |
| Ikarian Capital | $83,904 | 13.64% | 0.00% |
| Rhumbline | $49,457 | 8.04% | +66.23% |
| Manager | Value | % base | |
|---|---|---|---|
| Citadel | $154,404 | 25.09% | +48.50% |
| ADAR1 | $129,600 | 21.06% | 0.00% |
| Kestra Private Wealth Services | $99,970 | 16.25% | 0.00% |
| Ikarian Capital | $83,904 | 13.64% | 0.00% |
| Rhumbline | $49,457 | 8.04% | +66.23% |
+12.98%
shares held · 10 largest managers